

Prescribing Information

Test your knowledge on the coadministration of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) with other adult vaccines.



Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

See additional Important Safety Information continued below.

What Do You Think?

The coadministration of SHINGRIX has been studied with which of the following vaccines?

- A. FLUARIX Quadrivalent (Influenza Vaccine)
- B. PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent)
- C. BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)
- D. PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein])
- E. All of the above

Important Safety Information (cont'd)

- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see full Prescribing Information for SHINGRIX.

[For WAC pricing information for GSK Vaccine products: [VACCINES WAC](#)]



This email is intended for US healthcare professionals only.
Trademarks are property of their respective owners.

©2024 GSK or licensor.
PMUS-SGXEML240020 June 2024
Produced in USA.

[Contact Us](#) [Privacy Statement](#) [Legal Notices](#)

You are receiving this email because you agreed to receive information from Relevate Health regarding sponsored healthcare-related messages and communications from trusted third parties. To opt out from receiving future communications, Unsubscribe below.

This is a service from Relevate Health.

To ensure you continue to receive these emails, please add [\[shingles@education-on-vaccines.com\]](mailto:shingles@education-on-vaccines.com) to your address book.
Your participation in this activity is governed by the Relevate Health [Privacy Policy](#) and [Terms of Use](#).

[Unsubscribe](#)

From: Treatment Perspectives™ [shingles@education-on-vaccines.com]

To: [HCP email]

Subject Line: [Key Discoveries: Coadministering this vaccine with other adult vaccines]

Preheader: [Test your knowledge of vaccine coadministration]

Information from Industry

This email is funded and developed by GSK

Prescribing Information

Test your knowledge on the coadministration of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) with other adult vaccines.



Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

See additional Important Safety Information continued below.

What Do You Think?

The coadministration of SHINGRIX has been studied with which of the following vaccines?

- A. FLUARIX Quadrivalent (Influenza Vaccine)
- B. PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent)
- C. BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)
- D. PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein])
- E. All of the above

Important Safety Information (cont'd)

- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see full Prescribing Information for SHINGRIX.

[For WAC pricing information for GSK Vaccine products: [VACCINES WAC](#)]



This email is intended for US healthcare professionals only. Trademarks are property of their respective owners.

©2024 GSK or licensor.
PMUS-SGXEMPL240020 June 2024
Produced in USA.

[Contact Us](#) [Privacy Statement](#) [Legal Notices](#)

You are receiving this email because you agreed to receive information from Relevate Health regarding sponsored healthcare-related messages and communications from trusted third parties. To opt out from receiving future communications, Unsubscribe below.

This is a service from Relevate Health.

To ensure you continue to receive these emails, please add [shingles@education-on-vaccines.com] to your address book.

Your participation in this activity is governed by the Relevate Health [Privacy Policy](#) and [Terms of Use](#).

[Unsubscribe](#)

Relevate Health, 3825 Edwards Road, Suite 610, Cincinnati, OH 45209